Weight ManagementAlso known as: BI 456906, GLP-1/glucagon dual agonist BI
Survodutide
GLP-1/glucagon dual receptor agonist from Boehringer Ingelheim — in Phase 3 for obesity and Phase 2b for MASH. Demonstrates ~19% body weight reduction at highest dose.
Half-Life
~6-7 days
Dose Range
0.6-6 mg/week
Frequency
1× weekly
Vial Sizes
2.4 mg, 4.8 mg
Mechanism of Action
Dual agonist with balanced GLP-1R:GCGR activation ratio. GLP-1 component suppresses appetite and enhances insulin secretion; glucagon component drives hepatic fat oxidation, increases resting energy expenditure, and promotes MASH resolution.
Source: PMID: 38587239 (SYNCHRONIZE Phase 2)
Dosing Protocol
| Typical Dose | 0.6-6 mg/week |
| Frequency | 1× weekly |
| Half-Life | ~6-7 days |
| Common Vial Sizes | 2.4 mg, 4.8 mg |
Reconstitution Example
Vial
4.8 mg
Water
2 mL
Concentration
2.4 mg/mL
Per Unit (100u syringe)
24 mcg
Dose of 600 mcg = 25 units on a 100-unit insulin syringe
Dosing Quick Reference
Survodutide— Dosing Guide
Dose Range
0.6-6 mg/week
Half-Life
~6-7 days
Frequency
1× weekly
Route
Subcutaneous
2.4 mg vial4.8 mg vial
💧 2 mL BAC water|📐 2.4 mg/mL concentration|💉 24 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code